Drug Pipeline

IBI363 Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
5
Active Studies
1
Recruiting
1
Phase 3
4
Top Sponsors
Active Studies by Phase
Phase 3
1
Phase 2
1
Phase 1/2
2
Phase 1
1
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT07217301 IBI363 vs Docetaxel in Patients With Advanced Squamous Lung Cancer After Standard… iO Resistant sqNSCLC Recruiting
Phase 2
NCT07402070 IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer Resectable Stage II-III Non-small Cell Lung Cancer Not Yet Recruiting
Phase 1/2
NCT07307053 Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2) Rare Malignant Neoplasm Not Yet Recruiting
NCT07361991 IBI363 Plus Bevacizumab With or Without Nab-Paclitaxel for Second-Line Treatment of… Advan'ce'd Not Yet Recruiting
Phase 1
NCT05290597 A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in… Solid Malignancies or Lymphomas Active, Not Recruiting
Sponsors Running IBI363 Trials
Innovent Biologics (Suzhou) Co. Ltd. (2) Fortvita Biologics (USA)Inc. (1) Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) The First Affiliated Hospital of Zhengzhou University (1)
Disease Areas
Non-Small Cell Lung Cancer (NSCLC) (2) Lung Cancer (1)
Get alerts when IBI363 trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free